Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
New findings sits at the center of this dementia and brain health question.
Recent scientific discoveries have identified multiple new pathways through which reducing inflammation can protect brain health and slow cognitive decline. Researchers have found that the body possesses natural mechanisms—such as fat-derived molecules called epoxy-oxylipins—that act as an “off switch” for inflammation, and activating these mechanisms shows promise not only for arthritis and heart disease but potentially for preserving cognitive function in older adults. For families navigating dementia care, this emerging research suggests that inflammation management may become an increasingly important part of preventive strategies and complementary treatment approaches.
The connection between chronic inflammation and neurodegeneration has long been established, but recent breakthroughs offer new hope. Scientists have discovered that when certain inflammation-reducing molecules are boosted through targeted interventions, patients experience faster pain relief and reductions in harmful inflammatory cells. Meanwhile, clinical trials of novel anti-inflammatory medications are showing remarkably fast results—with one experimental drug reducing key inflammatory markers by 85 percent in just one week. These findings underscore why reducing inflammation should be a priority for anyone concerned about long-term brain health.
Table of Contents
- How Does the Body’s Natural Inflammation Control System Work?
- New Drugs Show Dramatic Speed in Lowering Inflammatory Markers
- Natural Plant-Based Approaches to Reducing Inflammation
- Why Inflammation Markers Matter for Cardiovascular and Brain Health
- Limitations of Inflammation Reduction as a Stand-Alone Strategy
- Practical Inflammation Reduction Strategies for Daily Life
- The Future of Inflammation-Targeting Therapies in Dementia Care
- Conclusion
How Does the Body’s Natural Inflammation Control System Work?
The human body has evolved sophisticated built-in mechanisms to control inflammation, but these systems can weaken or malfunction with age and chronic disease. Researchers recently identified epoxy-oxylipins, fat-derived molecules that function as the body’s natural “off switch” for inflammatory responses. When these molecules are present in sufficient quantities, they signal immune cells to stand down, reducing both inflammation and associated pain.
In laboratory and clinical research aimed at treating conditions like arthritis, scientists found that when they used drugs to boost levels of epoxy-oxylipins, patients experienced faster pain relief and significant reductions in the harmful white blood cells that drive inflammation. What makes this discovery particularly relevant for brain health is that the same inflammatory processes that damage joints and blood vessels also contribute to cognitive decline. The same immune cells that cause arthritis pain can accumulate in the brain and trigger neuroinflammation, a key driver of conditions like Alzheimer’s disease and Lewy body dementia. By understanding how to activate the body’s natural braking mechanisms on inflammation, researchers are opening new doors to preventive strategies that could potentially slow or reduce the progression of these neurodegenerative conditions.
New Drugs Show Dramatic Speed in Lowering Inflammatory Markers
Clinical trials have demonstrated that modern anti-inflammatory medications can work remarkably fast. BGE-102, an experimental pill being developed for cardiovascular risk prevention, achieved an 85 percent reduction in high-sensitivity C-reactive protein (hs-CRP)—a key marker of systemic inflammation—after just one week in study participants taking a 60-milligram dose. The trial enrolled people with obesity and elevated baseline inflammation levels, making them ideal candidates to measure the drug’s effectiveness. For context, hs-CRP levels above 3 mg/L are considered elevated and associated with increased risk of cardiovascular events and cognitive decline.
It’s important to note that while these rapid reductions in inflammatory markers are encouraging, the long-term benefits of maintaining such low hs-CRP levels still need to be evaluated in larger, longer-term studies. Additionally, not all patients respond equally to these medications, and some may experience side effects that limit their use. The impressive short-term results from Phase 1 trials are promising, but they represent early-stage evidence, not yet conclusive proof that rapid inflammation reduction will translate to sustained prevention of dementia or cardiovascular disease. Families considering any new medication for a relative with cognitive concerns should discuss the evidence and risks with their healthcare provider.
Natural Plant-Based Approaches to Reducing Inflammation
Beyond pharmaceuticals, traditional plant medicines are being scientifically validated for their anti-inflammatory effects. The Joseph’s Coat plant, used for centuries in Brazilian traditional medicine, has demonstrated strong safety and efficacy in both reducing inflammation and easing pain while also offering protection against arthritis in clinical studies. This plant represents the kind of integrative approach that may appeal to families seeking gentler, complementary strategies alongside conventional care.
The interest in natural anti-inflammatory compounds reflects a broader recognition that inflammation management doesn’t have to rely solely on pharmaceutical intervention. Some patients and families prefer to start with dietary and lifestyle modifications known to reduce inflammation—such as the Mediterranean diet, regular exercise, adequate sleep, and stress reduction—before exploring pharmaceutical options. That said, for people with advanced dementia or serious underlying health conditions, these natural approaches alone may not provide sufficient inflammation reduction, and medical oversight remains essential.
Why Inflammation Markers Matter for Cardiovascular and Brain Health
High-sensitivity C-reactive protein (hs-CRP) has emerged as one of the most reliable biomarkers for predicting future cardiovascular events. According to the 2025 American College of Cardiology Scientific Statement published in the JACC Journal, elevated hs-CRP remains strongly predictive of recurrent cardiovascular events even in patients already taking statin medications—the standard drug class for cholesterol management. This finding is particularly important because cardiovascular disease and dementia share many underlying risk factors, and people with heart disease face significantly higher dementia risk.
The strong relationship between hs-CRP levels and cardiovascular outcomes suggests that inflammation reduction may offer a two-fold benefit: protecting the heart and, by extension, protecting the brain. For older adults and those with cognitive concerns, getting hs-CRP tested alongside standard cardiovascular risk assessments could provide valuable information about inflammatory status and guide decisions about whether additional anti-inflammatory interventions might be warranted. However, hs-CRP is just one piece of the puzzle—a comprehensive approach to dementia prevention involves managing multiple risk factors including blood pressure, blood sugar, cognitive engagement, and social connection.
Limitations of Inflammation Reduction as a Stand-Alone Strategy
While reducing inflammation offers genuine promise for brain health, it’s crucial to recognize that inflammation is just one of several mechanisms contributing to cognitive decline. Amyloid-beta accumulation, tau tangles, vascular dysfunction, neuronal loss, and metabolic dysfunction all play roles in Alzheimer’s disease and other dementias, and inflammation is intertwined with but not identical to these processes. A medication that effectively lowers inflammation markers might not address other pathological changes occurring in the brain, and patients should not expect inflammation reduction alone to halt or reverse established dementia.
Additionally, chronic inflammation itself is often a consequence of other underlying problems—obesity, sedentary lifestyle, poor diet, chronic stress, untreated sleep apnea, and inadequately managed diabetes all drive inflammatory states. Treating the inflammation without addressing these root causes is somewhat like using a drain cleaner without fixing the clogged pipe. For genuine long-term dementia prevention and brain health, inflammation management works best as part of a comprehensive strategy that also targets lifestyle factors and manages other cardiovascular risk factors.
Practical Inflammation Reduction Strategies for Daily Life
For families seeking to reduce inflammation in relatives with or at risk for dementia, a combination of approaches tends to be more effective than any single intervention. Dietary strategies like emphasizing vegetables, fruits, fish, and healthy oils while limiting processed foods and added sugars have strong evidence supporting their anti-inflammatory effects. Regular physical activity—even 30 minutes of moderate exercise most days of the week—consistently reduces systemic inflammation levels.
Quality sleep, typically seven to nine hours nightly, is also fundamental, as sleep deprivation drives inflammation. Stress reduction practices including meditation, time in nature, social engagement, and other activities that bring joy have been shown to lower inflammatory markers. For someone already experiencing cognitive decline, engaging them in meaningful activities, maintaining social connections, and ensuring adequate rest often reduces behavioral symptoms and agitation, which themselves can reflect underlying inflammatory states. These approaches are accessible to nearly everyone, carry minimal risk of side effects, and provide benefits beyond inflammation reduction alone.
The Future of Inflammation-Targeting Therapies in Dementia Care
As researchers continue to develop more sophisticated understanding of how to activate the body’s natural inflammation-control mechanisms, the pipeline of new anti-inflammatory therapies targeting brain health will likely expand significantly. The success of epoxy-oxylipins and emerging drugs like BGE-102 in showing rapid, meaningful reductions in inflammatory markers suggests that better tools for inflammation management are on the horizon.
Future treatments may combine pharmaceutical interventions with biomarker monitoring, allowing clinicians to personalize anti-inflammatory strategies based on individual patterns of inflammation. The most promising path forward likely involves a precision medicine approach, where inflammation testing and anti-inflammatory interventions are tailored to an individual’s specific inflammatory profile and underlying disease mechanisms. For families dealing with dementia, staying informed about advances in inflammation-targeting therapies—while maintaining realistic expectations about what these treatments can achieve—will be important as clinical research continues to mature.
Conclusion
Recent scientific findings have reinforced what researchers increasingly understand: chronic inflammation is a significant modifiable risk factor for cognitive decline and dementia, and multiple strategies exist to reduce it. From activating the body’s natural epoxy-oxylipins to pharmaceutical interventions like BGE-102 showing remarkable speed in lowering inflammatory markers, to validated plant-based compounds and time-tested lifestyle modifications, the toolkit for inflammation management is expanding. For anyone concerned about brain health or caring for someone with dementia, this research underscores the importance of keeping inflammation in focus.
The path forward combines vigilance about inflammation with realistic recognition that reducing inflammation alone cannot prevent or reverse dementia. Instead, inflammation management works best as one component of a comprehensive approach that addresses cardiovascular health, lifestyle factors, cognitive engagement, and social connection. If you have concerns about cognitive health in yourself or a loved one, discuss inflammation screening and evidence-based anti-inflammatory strategies with your healthcare provider to determine what combination of approaches makes sense for your individual situation.
You Might Also Like
- Researchers Highlight Challenges in Accurate Diagnosis
- Research Opens Door to New Drug Development
- New Study Tests Experimental Intervention
For more, see Alzheimer’s Association.
